This post was originally published on this site
The company said it would cap the out-of-pocket cost of the diabetes drug at $35.
Eli Lilly and Company said on Wednesday that it would reduce the price of its most commonly prescribed insulins and expand a program that caps monthly out-of-pocket costs for patients at $35 or less.
It said the company was taking the action to “help Americans who may have difficulty navigating a complex health care system that may keep them from getting affordable insulin.”
Insulin, a lifesaving drug that is usually taken daily, has grown increasingly expensive in recent years, and many diabetes patients ration their medicines or discontinue them because of the cost. More than 30 million Americans live with diabetes.
It comes after years of mounting criticism from Americans who have said the drug should be more accessible. The criticism led to lawsuits and legislation.
This is a developing story. Check back for updates.